Dr. McCloskey is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
92 2nd St
Hackensack, NJ 07601Phone+1 551-996-3925Fax+1 551-996-0574
Education & Training
MedStar Health/Georgetown University HospitalFellowship, Hematology and Medical Oncology, 2011 - 2014- MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 2008 - 2011
Georgetown University School of MedicineClass of 2008
Certifications & Licensure
NJ State Medical License 2014 - 2025
DC State Medical License 2008 - 2024
VA State Medical License 2008 - 2016
Clinical Trials
- Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML Start of enrollment: 2009 Oct 01
- Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant Start of enrollment: 2019 Mar 08
- Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML Start of enrollment: 2018 Aug 15
- Join now to see all
Publications & Presentations
PubMed
- 4 citationsReliability of Cell-Free DNA and Targeted NGS in Predicting Chromosomal Abnormalities of Patients With Myeloid Neoplasms.Andrew Ip, Alexandra Della Pia, Gee Youn Geeny Kim, Jason Lofters, James Behrmann
Frontiers in Oncology. 2022-01-01 - 9 citationsOral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised...Guillermo Garcia-Manero, James McCloskey, Elizabeth A Griffiths, Karen W L Yee, Amer M Zeidan
The Lancet. Haematology. 2024-01-01 - 125 citationsIvosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 studyEytan M. Stein, Courtney D. DiNardo, Amir T. Fathi, Alice S. Mims, Keith W. Pratz
Blood. 2021-04-01
Abstracts/Posters
- Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ...James McCloskey, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing...James McCloskey, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Blinatumomab in Combination with Tyrosine Kinase Inhibitors Safely and Effectively Induces Rapid, Deep, and Durable Molecular Responses in Relapsed and Refractory Phil...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Molecular Epidemiologic Associations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) within the United States2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Opinion: The Pandemic and the RNA Sequencing GapSeptember 1st, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
